Abstract：
BACKGROUND: Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus (T2DM). So far, few severe side effects have been reported for it.
METHODS: A 41-year-old woman was admitted to the Emergency Room with diffuse abdominal pain. The patient had a known case of T2DM, fatty liver disease, and hypertension and was treated with Metformin, Liraglutide, and Losartan. Her liver functional test (LFT) was consistent with hepatocellular injury; however, laboratory tests and abdominal ultrasound were used to rule out autoimmune hepatitis. Due to concerns for drug-induced liver injury (DILL), liraglutide was discontinued and N-acetyl cysteine was prescribed. On the fifth day of hospitalization, the patient\'s symptoms resolved and his LFT started to decrease on the sixth day after 2 months, the patient\'s liver enzyme levels returned to normal.
CONCLUSIONS: Liraglutide is one of the most important drugs in the treatment of T2DM.The most common side effects of this drug are constipation, nausea, vomiting, diarrhea, indigestion, and loss of appetite. In rare cases, symptoms of thyroid cancer, pancreatitis, and hypoglycemia have been reported, however, DILL is one of the extremely rare side effect of Liraglutide. It is important to increase the awareness of physicians about the liver injury of Liraglutide.
METHODS: A 41-year-old woman was admitted to the Emergency Room with diffuse abdominal pain. The patient had a known case of T2DM, fatty liver disease, and hypertension and was treated with Metformin, Liraglutide, and Losartan. Her liver functional test (LFT) was consistent with hepatocellular injury; however, laboratory tests and abdominal ultrasound were used to rule out autoimmune hepatitis. Due to concerns for drug-induced liver injury (DILL), liraglutide was discontinued and N-acetyl cysteine was prescribed. On the fifth day of hospitalization, the patient\'s symptoms resolved and his LFT started to decrease on the sixth day after 2 months, the patient\'s liver enzyme levels returned to normal.
CONCLUSIONS: Liraglutide is one of the most important drugs in the treatment of T2DM.The most common side effects of this drug are constipation, nausea, vomiting, diarrhea, indigestion, and loss of appetite. In rare cases, symptoms of thyroid cancer, pancreatitis, and hypoglycemia have been reported, however, DILL is one of the extremely rare side effect of Liraglutide. It is important to increase the awareness of physicians about the liver injury of Liraglutide.
摘要：
背景：利拉鲁肽是一种胰高血糖素样肽-1（GLP-1）受体激动剂，用于治疗2型糖尿病（T2DM）。到目前为止,很少有严重副作用的报道。
方法：一名41岁女性因弥漫性腹痛进入急诊室。患者有一个已知的2型糖尿病病例，脂肪肝,高血压和二甲双胍治疗，利拉鲁肽,还有氯沙坦.她的肝功能检查（LFT）与肝细胞损伤一致；然而，实验室检查和腹部超声检查用于排除自身免疫性肝炎。由于对药物性肝损伤（DILL）的担忧，停用利拉鲁肽,并开出N-乙酰半胱氨酸处方.住院的第五天,2个月后的第六天，患者的症状得到缓解，LFT开始下降，患者的肝酶水平恢复正常。
结论：利拉鲁肽是治疗T2DM的重要药物之一。这种药物最常见的副作用是便秘，恶心,呕吐,腹泻,消化不良,和食欲不振。在极少数情况下,甲状腺癌的症状，胰腺炎,和低血糖的报道，然而,DILL是利拉鲁肽极为罕见的副作用之一。提高医师对利拉鲁肽肝损伤的认识非常重要。
方法：一名41岁女性因弥漫性腹痛进入急诊室。患者有一个已知的2型糖尿病病例，脂肪肝,高血压和二甲双胍治疗，利拉鲁肽,还有氯沙坦.她的肝功能检查（LFT）与肝细胞损伤一致；然而，实验室检查和腹部超声检查用于排除自身免疫性肝炎。由于对药物性肝损伤（DILL）的担忧，停用利拉鲁肽,并开出N-乙酰半胱氨酸处方.住院的第五天,2个月后的第六天，患者的症状得到缓解，LFT开始下降，患者的肝酶水平恢复正常。
结论：利拉鲁肽是治疗T2DM的重要药物之一。这种药物最常见的副作用是便秘，恶心,呕吐,腹泻,消化不良,和食欲不振。在极少数情况下,甲状腺癌的症状，胰腺炎,和低血糖的报道，然而,DILL是利拉鲁肽极为罕见的副作用之一。提高医师对利拉鲁肽肝损伤的认识非常重要。
